Soricimed Receives Innovation Award for Excellence in Bioscience
Moncton, NB, Canada, November 15, 2012 – Soricimed Biopharma was honoured yesterday, with an Innovation Award from New Brunswick’s Economic Development Minister, for Innovation Excellence in Biosciences.
(Economic Development Minister Paul Robichaud, left, presents Paul Gunn President and CEO of Soricimed Biopharma Inc. with the innovation award.)
“The leadership in innovation demonstrated by our entrepreneurs is helping create jobs and rebuild New Brunswick's economy,” said Economic Development Minister Paul Robichaud.
Soricimed Biopharma Inc. is a private clinical stage company developing novel cancer therapeutics and diagnostics. They are currently in a Phase I trial for their new cancer treatment drug and a pre-clinical study of a diagnostic blood test that can detect early stage ovarian, breast and prostate cancers. Soricimed holds six U.S. patents and one European patent covering 8 countries, as well as seven additional patent applications pending covering 14 countries.
“We are grateful to Minister Robichaud for promoting innovation in New Brunswick. It’s wonderful to be recognized in our home Province”, commented Paul Gunn, President & CEO of Soricimed Biopharma, “Soricimed’s research and development is highly innovative and it’s great to be able to provide truly meaningful bioscience work for our locally trained scientists.”
The awards ceremony served as the final event of a two-day forum on commercialization and productivity featuring industry experts and information sessions organized by the Department of Economic Development in co-operation with Springboard Atlantic, New Brunswick Innovation Foundation, Atlantic Canada Opportunities Agency, Entrepreneurs' Forum, and Public Works and Government Services Canada.
ABOUT SORICIMED BIOPHARMA
Soricimed Biopharma Inc., a private Canadian clinical stage company developing novel cancer therapeutics and diagnostics, was created in 2005 by Professor Jack Stewart and Paul Gunn following the discovery and development of a proprietary peptide, soricidin. Soricidin is the basis for Soricimed Biopharma Inc.’s targeted cancer management program focused on cancer therapeutics and diagnostics. Using focused innovative strategies in collaboration with major world-class cancer research institutions, Soricimed’s drugs have demonstrated a capability to reduce cancer cell viability, induce apoptosis and to reduce human tumour volume while minimizing side-effects in various classic animal and in vitro tumour models. Privately held, Soricimed is funded through private investors and various programs from the Government of Canada. For more information please visit, www.soricimed.com.
FOR MORE INFORMATION PLEASE CONTACT:
Julie Fotheringham - Partner, Hageman Communications